Annual CFF
$16.56 M
-$3.02 M-15.44%
31 December 2023
Summary:
Eterna Therapeutics annual cash flow from financing activities is currently $16.56 million, with the most recent change of -$3.02 million (-15.44%) on 31 December 2023. During the last 3 years, it has risen by +$11.89 million (+254.59%). ERNA annual CFF is now -73.12% below its all-time high of $61.59 million, reached on 31 December 2021.ERNA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$3.89 M
+$3.91 M+17768.18%
30 September 2024
Summary:
Eterna Therapeutics quarterly cash flow from financing activities is currently $3.89 million, with the most recent change of +$3.91 million (+17768.18%) on 30 September 2024. Over the past year, it has dropped by -$4.65 million (-54.48%). ERNA quarterly CFF is now -92.00% below its all-time high of $48.56 million, reached on 01 June 2021.ERNA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$12.95 M
-$4.65 M-26.43%
30 September 2024
Summary:
Eterna Therapeutics TTM cash flow from financing activities is currently $12.95 million, with the most recent change of -$4.65 million (-26.43%) on 30 September 2024. Over the past year, it has dropped by -$3.49 million (-21.23%). ERNA TTM CFF is now -79.64% below its all-time high of $63.63 million, reached on 01 March 2022.ERNA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ERNA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.4% | -54.5% | -21.2% |
| 3 y3 years | +254.6% | +11.0% | -79.2% |
| 5 y5 years | - | - | - |
ERNA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -73.1% | +254.6% | -67.6% | +1027.7% | -79.6% | +70.8% |
| 5 y | 5 years | -73.1% | +254.6% | -92.0% | +1027.7% | -79.6% | +4045.3% |
| alltime | all time | -73.1% | +254.6% | -92.0% | +1027.7% | -79.6% | +4045.3% |
Eterna Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.89 M(<-9900.0%) | $12.95 M(-26.4%) |
| June 2024 | - | -$22.00 K(-101.6%) | $17.61 M(-1.9%) |
| Mar 2024 | - | $1.39 M(-82.0%) | $17.94 M(+8.4%) |
| Dec 2023 | $16.56 M(-15.4%) | $7.70 M(-9.8%) | $16.56 M(+0.7%) |
| Sept 2023 | - | $8.54 M(+2637.2%) | $16.45 M(+107.9%) |
| June 2023 | - | $312.00 K(>+9900.0%) | $7.91 M(+4.3%) |
| Mar 2023 | - | $0.00(-100.0%) | $7.59 M(-61.3%) |
| Dec 2022 | $19.58 M | $7.59 M(>+9900.0%) | $19.58 M(+69.3%) |
| Sept 2022 | - | $6000.00(-146.2%) | $11.57 M(-23.2%) |
| June 2022 | - | -$13.00 K(-100.1%) | $15.06 M(-76.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $11.99 M(-2962.3%) | $63.63 M(+3.3%) |
| Dec 2021 | $61.59 M(+1219.0%) | - | - |
| Dec 2021 | - | -$419.00 K(-112.0%) | $61.59 M(-1.0%) |
| Sept 2021 | - | $3.50 M(-92.8%) | $62.23 M(+5.5%) |
| June 2021 | - | $48.56 M(+388.4%) | $59.00 M(+312.6%) |
| Mar 2021 | - | $9.94 M(+4313.2%) | $14.30 M(+206.3%) |
| Dec 2020 | $4.67 M | $225.30 K(-18.1%) | $4.67 M(+5.1%) |
| Sept 2020 | - | $275.00 K(-92.9%) | $4.44 M(+6.6%) |
| June 2020 | - | $3.86 M(+1134.0%) | $4.17 M(+1234.0%) |
| Mar 2020 | - | $312.50 K | $312.50 K |
FAQ
- What is Eterna Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Eterna Therapeutics?
- What is Eterna Therapeutics annual CFF year-on-year change?
- What is Eterna Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Eterna Therapeutics?
- What is Eterna Therapeutics quarterly CFF year-on-year change?
- What is Eterna Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Eterna Therapeutics?
- What is Eterna Therapeutics TTM CFF year-on-year change?
What is Eterna Therapeutics annual cash flow from financing activities?
The current annual CFF of ERNA is $16.56 M
What is the all time high annual CFF for Eterna Therapeutics?
Eterna Therapeutics all-time high annual cash flow from financing activities is $61.59 M
What is Eterna Therapeutics annual CFF year-on-year change?
Over the past year, ERNA annual cash flow from financing activities has changed by -$3.02 M (-15.44%)
What is Eterna Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ERNA is $3.89 M
What is the all time high quarterly CFF for Eterna Therapeutics?
Eterna Therapeutics all-time high quarterly cash flow from financing activities is $48.56 M
What is Eterna Therapeutics quarterly CFF year-on-year change?
Over the past year, ERNA quarterly cash flow from financing activities has changed by -$4.65 M (-54.48%)
What is Eterna Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ERNA is $12.95 M
What is the all time high TTM CFF for Eterna Therapeutics?
Eterna Therapeutics all-time high TTM cash flow from financing activities is $63.63 M
What is Eterna Therapeutics TTM CFF year-on-year change?
Over the past year, ERNA TTM cash flow from financing activities has changed by -$3.49 M (-21.23%)